Astec LifeSciences ASTEC
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Research path: Interpret Astec LifeSciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
AI analysis and Advanced tools for ASTEC
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 942.04 | 881.42 | 974.93 |
| Accumulated Depreciation Total | -286.97 | -242.96 | -199.63 |
| Other Liabilities Total | 1.3 | 0.66 | 2.49 |
| Accrued Expenses | 0.56 | 0.51 | 0.4 |
| Long Term Debt | 50 | 280 | 199 |
| Common Stock Total | 22.28 | 19.61 | 19.61 |
| Other Equity Total | -0.01 | 0.01 | 0.01 |
| Other Current Assets Total | 2.77 | 2.41 | 2.17 |
| Prepaid Expenses | 3.92 | 4.68 | 5.01 |
| Total Assets | 942.04 | 881.42 | 974.93 |
| Current Portof LT Debt/Capital Leases | 89.06 | 10.18 | 11.94 |
| Additional Paid-In Capital | 295.03 | 61.39 | 61.09 |
| Cash | 10.05 | 0.58 | 0.47 |
| Total Equity | 390.61 | 234.75 | 369.29 |
| Long Term Investments | 0.01 | 0.01 | 0.01 |
| Retained Earnings(Accumulated Deficit) | 73.19 | 153.62 | 288.2 |
| Total Common Shares Outstanding | 2.23 | 1.98 | 1.98 |
| Property/Plant/Equipment Total-Gross | 740.8 | 739.66 | 731.21 |
| Tangible Book Valueper Share Common Eq | 164.19 | 106.92 | 177.07 |
| Total Liabilities | 551.43 | 646.68 | 605.64 |
| Total Debt | 448.93 | 554.54 | 493.89 |
| Cashand Short Term Investments | 10.05 | 0.58 | 0.47 |
| Total Receivables Net | 285.94 | 171.51 | 193.69 |
| Notes Payable/Short Term Debt | 309.87 | 264.37 | 282.96 |
| Deferred Income Tax | 0.04 | 0.04 | 6.76 |
| Accounts Receivable-Trade Net | 247.72 | 147.52 | 169.07 |
| Property/Plant/Equipment Total-Net | 453.83 | 496.7 | 531.58 |
| Minority Interest | 0.31 | 0.27 | 0.23 |
| Total Current Liabilities | 499.79 | 365.71 | 397.16 |
| Total Inventory | 140.32 | 161.96 | 197.16 |
| ESOP Debt Guarantee | 0.12 | 0.11 | 0.38 |
| Accounts Payable | 87.67 | 81.61 | 89.28 |
| Other Currentliabilities Total | 12.63 | 9.05 | 12.58 |
| Total Long Term Debt | 50 | 280 | 199 |
| Intangibles Net | 24.75 | 23.45 | 19.42 |
| Other Long Term Assets Total | 1.35 | 1.36 | 1.73 |
| Note Receivable-Long Term | 19.11 | 18.77 | 23.71 |
| Total Current Assets | 442.99 | 341.14 | 398.49 |
Valuation and ratios
Growth
Debt 5Yr CAGR %19.12
Margins
Operating Margin 12m-11.5
Operating Margin 5y Avg-1.57
Net Profit Margin 12m-18.05
Net Profit Margin 5y-5.67
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio3.34
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk56.93
Analyst consensus
ConsensusSell
Consensus score4.00
Analyst opinions1
Strong Sell count0
Sell count1
Hold count0
Buy count0
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Asian Paints | INR 2,690.2 | 2.58 L | 58.14 | — |
| Solar Industries India | INR 18,921.6 | 1.71 L | 102.64 | — |
| Pidilite Industries | INR 1,573.95 | 1.60 L | 64.75 | — |
| SRF | INR 2,865 | 85,167.59 | 44.53 | — |
| Linde India | INR 6,895 | 58,803.47 | 108.69 | — |
Ownership
- Promoter
- 71.96%
- FII
- 0.01%
- MF
- 3.02%
- Other
- 25.01%
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Jubilant FoodWorks: Nippon India MF ची मोठी खरेदी! कंपनीतील हिस्सेदारी वाढवली Whalesbook
Astec Lifesciences Ltd is Rated Sell by MarketsMOJO MarketsMojo
Astec LifeSciences Schedules 32nd AGM on July 31, 2026; Reports Revenue Recovery in FY 2025-26 scanx.trade
Astec Lifesciences Turns EBITDA Positive, Reduces Net Loss in FY26 Whalesbook
Astec LifeSciences announces 32nd AGM and book closure dates BusinessUpturn
Astec LifeSciences announces 32nd AGM and closure of share transfer books BusinessUpturn
Events
- annual General MeetingAGM
- annual General MeetingPOM
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- rightsRights issue of equity shares of Rs. 10/- in the ratio of 1:7 @ premium of Rs. 880/-.
- annual General MeetingPOM
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results & Others
Discussion and sentiment for Astec LifeSciences
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Community discussion loads as you approach this section.
Business information
What the company does
Astec LifeSciences Limited is an India-based company, which is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. The Company undertakes contract development and manufacturing services for a diverse range of agrochemicals. The Company operates through a single segment, namely Agrochemicals. Its product categories include Fungicide, Growth Regulator, Intermediates, Insecticide, and Herbicide. Its products include Azimsulfuron, Halosulfuron, Flutriafol, Rimsulfuron, Transfluthrin, Prothiaconazole, Metalaxyl, Cyproconazole, and Tribenuron methyl. It has a sales mix of both exports and domestic sales. It exports to approximately 17 countries, including the United States and countries across Europe, West Asia, South-East Asia, Latin America and Africa. The Company has approximately nine manufacturing plants, which are located in Maharashtra.
Company facts
- Industry
- Chemical Manufacturing
- Sector
- Chemical Manufacturing
- NSE Code
- ASTEC
- BSE Code
- 533138
Stock FAQ
What is the symbol and ISIN of Astec LifeSciences?
Astec LifeSciences has the symbol ASTEC and ISIN - INE563J01010.
What is the latest recorded price of Astec LifeSciences?
The latest available recorded price of Astec LifeSciences is INR 669.60 as of 2026-07-22T06:35:12.081Z. This is a source-stamped snapshot, not a live quote.
What are the year high and year low of Astec LifeSciences?
Year high: INR 936.00. Year low: INR 512.35.
What is the market capitalization of Astec LifeSciences?
Market capitalization: INR 1,496.04 crore.
What is the dividend yield of Astec LifeSciences?
Dividend yield: 0.00%.
How is the financial performance of Astec LifeSciences based on revenue, net income, and EPS?
Revenue: INR 448.15 crore. Net income: INR -80.92 crore. EPS: INR -37.98.
What is the book value of Astec LifeSciences?
Book value: INR 164.19.
What are the price-to-book and price-to-sales ratios of Astec LifeSciences?
Price-to-book ratio: 4.08. Price-to-sales ratio: 3.34.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.

